Table 3.
Multivariate modela | Univariate model | |||
---|---|---|---|---|
Unrestricted | Lower limit of 80 % sensitivityb,c | Unrestricted | Lower limit of 80 % sensitivityb,c | |
Sensitivityc estimate [95 % CI] | 88.8 % [82.2 %; 93.6 %] | 88.8 % [82.2 %; 93.6 %] | 73.1 % [64.8 %; 80.4 %] | 86.6 % [79.6 %; 91.8 %] |
Specificityd estimate [95 % CI] | 63.2 % [58.4 %; 67.9 %] | 63.2 % [58.4 %; 67.9 %] | 75.0 % [70.5 %; 79.1 %] | 54.9 % [49.9 %; 59.8 %] |
Leave-one-out cross validation e | ||||
Sensitivityc estimate [95 % CI] | 80.6 % [72.9 %; 86.9 %] | 81.3 % [73.7 %; 87.5 %] | 71.6 % [63.2 %; 79.1 %] | 85.8 % [78.7 %; 91.2 %] |
Specificityd estimate [95 % CI] | 61.5 % [56.6 %; 66.3 %] | 61.5 % [56.6 %; 66.3 %] | 75.0 % [70.5 %; 79.1 %] | 54.9 % [49.9 %; 59.8 %] |
aA multivariate logistic regression model considering age and gender besides MFAP4 serum levels was derived and the respective Youden optimal cutoffs were determined
bCutoff optimization was restricted to a minimum sensitivity of 80 % accounting for the importance of the identification of high fibrosis stages
cSensitivity was defined as probability of classifying stages F3 and F4 correctly
dSpecificity was defined as probability of classifying stages F0 to F2 correctly
eAs sensitivity and specificity values are prone to overoptimism in the analysis of the complete data set leave-one-out cross validation was performed to obtain unbiased estimates